SAN DIEGO - Johnson & Johnson (NYSE:JNJ) has announced results from their Phase 2 SKIPPirr study, indicating a significant reduction in infusion-related reactions (IRRs) in patients with advanced non-small cell lung cancer (NSCLC) treated with RYBREVANT® (amivantamab-vmjw). The study, presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer, showed that a pre-medication regimen of dexamethasone decreased IRRs from a historical rate of 67.4% to 22.5%.
The SKIPPirr study involved 40 patients with NSCLC harboring specific mutations, who received an 8-mg dose of oral dexamethasone twice daily for two days before the first infusion of IV RYBREVANT®. The results met the primary endpoint for the incidence of IRRs at Cycle 1 Day 1 (C1D1). All IRRs reported were Grade 1 or 2, with no hospitalizations or Grade 3 or higher IRR events.
Dr. Gilberto Lopes, the study's presenting author and associate director of global oncology at Sylvester Comprehensive Cancer Center, highlighted the importance of these findings in potentially improving patient experience with intravenous amivantamab treatment.
Mark Wildgust, Ph.D., Vice President of Oncology Global Medical Affairs at Johnson & Johnson, emphasized the importance of reducing IRR risk to improve the overall treatment experience. The incorporation of oral dexamethasone into the regimen aims to mitigate this risk and allow patients to continue therapy with fewer interruptions.
RYBREVANT®, a bispecific antibody targeting EGFR and MET, is approved in various markets for the treatment of NSCLC with specific EGFR mutations. Ongoing studies continue to evaluate prophylactic strategies to further reduce IRRs in patients receiving the treatment.
This news is based on a press release statement and has not been independently verified. Further information about the SKIPPirr study and RYBREVANT® can be found on clinical trial registries and the manufacturer's official website.
In other recent news, Johnson & Johnson (J&J) has announced the retirement of D. S. Davis from its board of directors, as well as the retirement of Executive Vice President and Chief Human Resources Officer, Dr. Peter M. Fasolo. Kristen Mulholland will succeed Dr. Fasolo. In legal developments, J&J has increased its proposed settlement amount by $1.1 billion to address lawsuits related to its talc-based products, and has been ordered to pay $1 billion to Auris Health shareholders for breaching a 2019 merger agreement.
In the pharmaceutical sector, J&J has submitted a Biologics License Application to the U.S. Food and Drug Administration for the approval of nipocalimab, a treatment for generalized myasthenia gravis. These are some of the recent developments for Johnson & Johnson, reflecting a period of executive transition, legal resolution, and ongoing pharmaceutical innovation.
InvestingPro Insights
Johnson & Johnson (NYSE:JNJ), a leading pharmaceutical giant, recently showcased promising results from their SKIPPirr study at the IASLC 2024 World Conference on Lung Cancer. As investors consider the potential market impact of these findings, it's essential to note Johnson & Johnson's robust financial metrics that could support ongoing research and development efforts.
InvestingPro Data reveals a strong financial position for JNJ, with a substantial market capitalization of $403.62 billion and a solid revenue stream, marked by a growth rate of 5.13% over the last twelve months as of Q2 2024. The company's gross profit margin stands impressively high at 69.43%, reflecting efficient operations and cost management.
An InvestingPro Tip highlights that Johnson & Johnson has raised its dividend for 54 consecutive years, demonstrating a commitment to delivering shareholder value consistently. This track record of dividend growth may appeal to investors looking for stable returns, especially in the dynamic pharmaceutical industry.
Additionally, Johnson & Johnson trades at a low P/E ratio relative to near-term earnings growth, which could indicate that the stock is undervalued in the context of its growth prospects. This is particularly relevant given the positive results from the SKIPPirr study that could lead to further market penetration and sales growth for RYBREVANT®.
For investors interested in a deeper dive into Johnson & Johnson's financial health and market potential, InvestingPro offers additional insights and metrics. Currently, there are numerous InvestingPro Tips available on https://www.investing.com/pro/JNJ, which provide a more comprehensive analysis for those considering an investment in this pharmaceutical leader.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.